Senthil Vel
Chief Medical Officer
Senthil is a senior clinician and a Fellow of the Faculty of Pharmaceutical Physician, the medical specialty concerned with the research, development, and monitoring of medicines. He has led large medical teams across EMEA, APAC and US. He worked for large and mid-sized pharmaceutical and medical device companies in clinical research, regulatory, safety and medical affairs. He comes from his current role as the Chief Medical Officer of BPL.
Sen qualified in medicine and trained in surgery under the Royal College of Surgeons of England. He completed a full time MBA at Cranfield School of Management and completed his pharmaceutical training under the faculty of Pharmaceutical Medicine.
Sen has over 18 years’ experience is pharmaceutical medicine and has worked in London, Zurich, Hong Kong and US in pharmaceuticals and medical devices. He has managed several agency submissions including FDA and EMA.
Sen’s experience includes designing clinical strategy to support the regulatory requirement of FDA, EMA and MHRA and other major agencies across the world.
He has extensive experience in translational work and has been involved in designing several Phase I to Phase IV clinical studies for pharmaceuticals and devices both for harm reduction and efficacy claims across several disease areas
Sen has provided medical oversight to clinical studies and support to the Clinical Research team. He has been involved in analysis and interpretation of clinical trial data and the reporting of clinical trial results via poster and podium presentations and has authored peer- reviewed publications.
Sen has experience of stakeholder management driving national and international health policy and guidelines with medical societies, agencies, and international bodies. He has lectured in various conference and has chaired several boards and been the spokesperson for medical related matters. He belongs to several medical groups and is well networked in the medical community. He has an interest in Epidemiology and has structured Epi and modelling studies for disease area awareness, safety and efficacy claims.
